Disc Medicine Inc

NASDAQ:IRONUnited States

Nov 12, 2024

Show headlines and story abstract

• Wedbush Raises Disc Medicine Price Target to $83 From $75, Maintains Outperform Rating, from 2:11PM ET on Tuesday Nov 12, 2024 by MT Newswires

  2:11PM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: IRON
  02:11 PM EST, 11/12/2024 (MT Newswires) -- Disc Medicine (IRON) has an average rating of buy and price targets ranging from $70 to $112, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from ma...

• Disc Medicine's Q3 Net Loss Widens, from 9:08AM ET on Tuesday Nov 12, 2024 by MT Newswires

  9:08AM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: IRON
  09:08 AM EST, 11/12/2024 (MT Newswires) -- Disc Medicine (IRON) reported a Q3 loss Tuesday of $0.89 per share, wider than a loss of $0.58 a year earlier. Analysts polled by Capital IQ expected a loss of $0.99. As expected, no revenue for the quarter...

• Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

  8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: IRON
  
  diseases; the timing and anticipated results of Disc's preclinical studies and clinical trials and the risk that the results of Disc's preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval; and the other risks and uncertainties described in Disc's filings with the SEC, including in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2023, and in subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date on which it was made. None of Disc, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law.